Objective Untreated patients with small, single hepatocellular carcinoma (HCC) in compensated cirrhosis are characterized by a relatively good prognosis. Methods We report the findings generated in a retrospective study on a cohort of 186 consecutive patients with small (< 5 cm) HCC in Child A or B cirrhosis, who were transplanted (four), underwent surgery (15), or were treated with percutaneous ethanol injection (117), lipiodol chemoembolization (44) or best supportive care (six), depending on their clinical features. Results Overall survival was 26% at 5 years (31% Child A, 20% Child B), with a mean and median survival of 44 and 38 months, respectively. The longest survival was obtained with transplantation and surgery, and the worst with best supportive care. When untreated patients were not considered, no significant differences were observed between the different types of treatment, however, even when patients in the Child A group were considered alone. Almost all the patients who underwent surgery relapsed. No significant difference was observed in relation to the stage of the disease, while α-fetoprotein levels were singled out as the only relevant prognostic factor in a multivariate Cox’s regression model. Costs per year of life saved were extremely high for transplantation and lowest for ethanol injection, with surgery being less expensive than chemoembolization. Conclusions This study confirms that patients with single, small HCC nodules in well compensated cirrhosis should be treated. The choice of type of treatment should be based on the availability of local resources and expertise, and on the patients’ preference, after they have been properly informed on the survival, morbidity and mortality related to each treatment option. The relative cost of the procedures should also be considered.

Farinati, F., Gianni, S., Marin, G., Fagiuoli, S., Rinaldi, M., Naccarato, R. (2001). Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 13(10), 1217-1224 [10.1097/00042737-200110000-00015].

Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?

FAGIUOLI S;
2001

Abstract

Objective Untreated patients with small, single hepatocellular carcinoma (HCC) in compensated cirrhosis are characterized by a relatively good prognosis. Methods We report the findings generated in a retrospective study on a cohort of 186 consecutive patients with small (< 5 cm) HCC in Child A or B cirrhosis, who were transplanted (four), underwent surgery (15), or were treated with percutaneous ethanol injection (117), lipiodol chemoembolization (44) or best supportive care (six), depending on their clinical features. Results Overall survival was 26% at 5 years (31% Child A, 20% Child B), with a mean and median survival of 44 and 38 months, respectively. The longest survival was obtained with transplantation and surgery, and the worst with best supportive care. When untreated patients were not considered, no significant differences were observed between the different types of treatment, however, even when patients in the Child A group were considered alone. Almost all the patients who underwent surgery relapsed. No significant difference was observed in relation to the stage of the disease, while α-fetoprotein levels were singled out as the only relevant prognostic factor in a multivariate Cox’s regression model. Costs per year of life saved were extremely high for transplantation and lowest for ethanol injection, with surgery being less expensive than chemoembolization. Conclusions This study confirms that patients with single, small HCC nodules in well compensated cirrhosis should be treated. The choice of type of treatment should be based on the availability of local resources and expertise, and on the patients’ preference, after they have been properly informed on the survival, morbidity and mortality related to each treatment option. The relative cost of the procedures should also be considered.
Articolo in rivista - Articolo scientifico
Cirrhosis; Cost effectiveness; Hepatocellular carcinoma; Survival; Treatment;
English
1217
1224
8
Farinati, F., Gianni, S., Marin, G., Fagiuoli, S., Rinaldi, M., Naccarato, R. (2001). Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 13(10), 1217-1224 [10.1097/00042737-200110000-00015].
Farinati, F; Gianni, S; Marin, G; Fagiuoli, S; Rinaldi, M; Naccarato, R
File in questo prodotto:
File Dimensione Formato  
Farinati F. (2001) Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis.pdf

Solo gestori archivio

Dimensione 3.72 MB
Formato Adobe PDF
3.72 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353894
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
Social impact